BCL2 and acquired polycythemia vera: Strikingly, Bcl-2 downregulation with shRNA (Figs. 6K, L) or venetoclax (Fig. 6M) also benefited the enucleation of PV patient-derived erythroblasts, which was consistent with the outcome of miR-125b-5p overexpression.